Stephens Investment Management Group LLC Increases Holdings in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX)

Stephens Investment Management Group LLC lifted its holdings in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) by 5.1% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 942,969 shares of the company’s stock after buying an additional 45,514 shares during the period. Pacira Pharmaceuticals comprises 1.1% of Stephens Investment Management Group LLC’s holdings, making the stock its 27th largest holding. Stephens Investment Management Group LLC owned approximately 2.35% of Pacira Pharmaceuticals worth $44,980,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the company. Timpani Capital Management LLC bought a new stake in shares of Pacira Pharmaceuticals in the 2nd quarter worth about $3,466,000. Baillie Gifford & Co. increased its holdings in shares of Pacira Pharmaceuticals by 40.9% in the 2nd quarter. Baillie Gifford & Co. now owns 301,000 shares of the company’s stock worth $14,358,000 after buying an additional 87,400 shares during the last quarter. Eaton Vance Management bought a new stake in shares of Pacira Pharmaceuticals in the 2nd quarter worth about $19,519,000. Schroder Investment Management Group increased its holdings in shares of Pacira Pharmaceuticals by 0.7% in the 2nd quarter. Schroder Investment Management Group now owns 935,168 shares of the company’s stock worth $45,075,000 after buying an additional 6,641 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. bought a new stake in shares of Pacira Pharmaceuticals in the 2nd quarter worth about $114,000.

Shares of Pacira Pharmaceuticals, Inc. (PCRX) opened at 37.50 on Tuesday. Pacira Pharmaceuticals, Inc. has a 52-week low of $29.95 and a 52-week high of $58.95. The firm has a 50-day moving average of $36.91 and a 200 day moving average of $44.24. The stock’s market capitalization is $1.51 billion.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings results on Wednesday, August 2nd. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.06). The business had revenue of $70.90 million for the quarter, compared to analyst estimates of $73.37 million. Pacira Pharmaceuticals had a negative net margin of 23.36% and a negative return on equity of 12.44%. Pacira Pharmaceuticals’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same period last year, the business posted $0.21 earnings per share. Equities research analysts forecast that Pacira Pharmaceuticals, Inc. will post ($0.17) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://ledgergazette.com/2017/09/26/stephens-investment-management-group-llc-buys-45514-shares-of-pacira-pharmaceuticals-inc-pcrx.html.

A number of analysts have recently weighed in on the stock. BMO Capital Markets reduced their target price on shares of Pacira Pharmaceuticals from $42.00 to $40.00 and set a “market perform” rating on the stock in a report on Thursday, August 3rd. Mizuho restated a “buy” rating and issued a $53.00 target price on shares of Pacira Pharmaceuticals in a report on Monday. Wedbush reaffirmed an “outperform” rating and set a $87.00 price target on shares of Pacira Pharmaceuticals in a research note on Wednesday, June 21st. Canaccord Genuity reaffirmed a “buy” rating and set a $56.00 price target on shares of Pacira Pharmaceuticals in a research note on Monday, July 31st. Finally, HC Wainwright set a $59.00 price target on shares of Pacira Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Two analysts have rated the stock with a sell rating, ten have given a hold rating and nine have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $52.92.

In related news, Director Paul J. Hastings sold 1,044 shares of Pacira Pharmaceuticals stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $36.15, for a total transaction of $37,740.60. Following the transaction, the director now directly owns 3,518 shares of the company’s stock, valued at $127,175.70. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CAO Kristen Marie Williams sold 3,461 shares of Pacira Pharmaceuticals stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $36.75, for a total value of $127,191.75. Following the transaction, the chief accounting officer now directly owns 21,312 shares in the company, valued at $783,216. The disclosure for this sale can be found here. Ins

Several other institutional investors have also bought and sold shares of the company. Timpani Capital Management LLC bought a new stake in shares of Pacira Pharmaceuticals in the 2nd quarter worth about $3,466,000. Baillie Gifford & Co. increased its holdings in shares of Pacira Pharmaceuticals by 40.9% in the 2nd quarter. Baillie Gifford & Co. now owns 301,000 shares of the company’s stock worth $14,358,000 after buying an additional 87,400 shares during the last quarter. Eaton Vance Management bought a new stake in shares of Pacira Pharmaceuticals in the 2nd quarter worth about $19,519,000. Schroder Investment Management Group increased its holdings in shares of Pacira Pharmaceuticals by 0.7% in the 2nd quarter. Schroder Investment Management Group now owns 935,168 shares of the company’s stock worth $45,075,000 after buying an additional 6,641 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. bought a new stake in shares of Pacira Pharmaceuticals in the 2nd quarter worth about $114,000.

Shares of Pacira Pharmaceuticals, Inc. (PCRX) opened at 37.50 on Tuesday. Pacira Pharmaceuticals, Inc. has a 52-week low of $29.95 and a 52-week high of $58.95. The firm has a 50-day moving average of $36.91 and a 200 day moving average of $44.24. The stock’s market capitalization is $1.51 billion.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings results on Wednesday, August 2nd. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.06). The business had revenue of $70.90 million for the quarter, compared to analyst estimates of $73.37 million. Pacira Pharmaceuticals had a negative net margin of 23.36% and a negative return on equity of 12.44%. Pacira Pharmaceuticals’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same period last year, the business posted $0.21 earnings per share. Equities research analysts forecast that Pacira Pharmaceuticals, Inc. will post ($0.17) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://ledgergazette.com/2017/09/26/stephens-investment-management-group-llc-buys-45514-shares-of-pacira-pharmaceuticals-inc-pcrx.html.

A number of analysts have recently weighed in on the stock. BMO Capital Markets reduced their target price on shares of Pacira Pharmaceuticals from $42.00 to $40.00 and set a “market perform” rating on the stock in a report on Thursday, August 3rd. Mizuho restated a “buy” rating and issued a $53.00 target price on shares of Pacira Pharmaceuticals in a report on Monday. Wedbush reaffirmed an “outperform” rating and set a $87.00 price target on shares of Pacira Pharmaceuticals in a research note on Wednesday, June 21st. Canaccord Genuity reaffirmed a “buy” rating and set a $56.00 price target on shares of Pacira Pharmaceuticals in a research note on Monday, July 31st. Finally, HC Wainwright set a $59.00 price target on shares of Pacira Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Two analysts have rated the stock with a sell rating, ten have given a hold rating and nine have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $52.92.

In related news, Director Paul J. Hastings sold 1,044 shares of Pacira Pharmaceuticals stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $36.15, for a total transaction of $37,740.60. Following the transaction, the director now directly owns 3,518 shares of the company’s stock, valued at $127,175.70. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CAO Kristen Marie Williams sold 3,461 shares of Pacira Pharmaceuticals stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $36.75, for a total value of $127,191.75. Following the transaction, the chief accounting officer now directly owns 21,312 shares in the company, valued at $783,216. The disclosure for this sale can be found here. Insiders have sold 33,390 shares of company stock worth $1,215,480 over the last three months. Corporate insiders own 6.60% of the company’s stock.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply